{
Intra-Cellular Therapies, Inc.

Companies

}
001122334455554433221100
001122334455554433221100
Symbol ITCI
Name Intra-Cellular Therapies, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State NY
City New York
Zipcode 10016
Website http://www.intracellulartherapies.com
Track all markets on TradingView

ubs maintains buy rating for johnson and johnson with strong growth prospects

UBS has reaffirmed its Buy rating for Johnson & Johnson, setting a price target of $180, despite challenges from talc-related lawsuits. Analysts are optimistic about the company's core business and growth in prescriptions for Tremfya, particularly with upcoming approvals for Crohn's disease and ulcerative colitis treatments.RBC Capital Markets also maintains an Outperform rating with a $181 target, highlighting the potential of RYBREVANT and LAZCLUZE in the lung cancer market. Moody's has affirmed Johnson & Johnson's strong financial position, noting its ability to manage legal liabilities effectively.
Investing.com
United States Dollar Intra-Cellular Therapies, Inc. Johnson & Johnson USA
Business & Industry, Market Report
17:40 04.04.2025

jpmorgan conference highlights major acquisitions and strategic plans in healthcare industry

At the J.P. Morgan Healthcare Conference, Pfizer CEO Albert Bourla addressed an impending $17B 'LOE wave' due to patent losses, while highlighting acquisitions expected to generate $20B in annual sales by 2030. Johnson & Johnson announced a $14.6B acquisition of Intra-Cellular Therapies, aiming to enhance its portfolio with the FDA-approved drug Caplyta. Meanwhile, Moderna revealed a significant cut to its 2025 sales guidance, prompting a 20% drop in its stock.
Fierce Pharma
United States Dollar Intra-Cellular Therapies, Inc. Johnson & Johnson Vertex, Inc. Pfizer Inc. Moderna, Inc. USA Albert Bourla Joaquin Duato Reshma Kewalramani Show more
Finance & Economy, Market Report
20:35 13.01.2025

intra-cellular therapies stock surges after caplyta patent litigation settlement

Intra-Cellular Therapies (ITCI) shares surged nearly 15% following a settlement with Sandoz over Caplyta patent litigation, allowing Sandoz to sell generics starting July 1, 2040, under certain conditions. This agreement secures ITCI's market position for Caplyta, its sole revenue-generating product, which saw a 46% sales increase in early 2024. The company continues to pursue similar litigation against other parties.
Yahoo Finance
United States Dollar Novartis AG Sandoz Group AG Intra-Cellular Therapies, Inc. Johnson & Johnson USA Show more
Regulatory & Legal, Market Report
17:40 13.01.2025

Intra-Cellular secures favorable settlement with Sandoz for Caplyta patent litigation

Intra-Cellular Therapies has reached a settlement with Sandoz regarding patent litigation for its product Caplyta, marking Sandoz as the first of seven ANDA filers to finalize a deal. RBC Capital views the favorable terms as a positive sign for Caplyta's revenue stability and maintains an Outperform rating with a $108 price target on the shares.
Yahoo Finance
Sandoz Group AG Intra-Cellular Therapies, Inc. USA
Regulatory & Legal, Market Report
16:40 11.01.2025

Intra-Cellular Therapies shares rise after Sandoz patent dispute settlement

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) rose following the resolution of a patent dispute with Sandoz (OTCQX:SDZNY) regarding its antipsychotic drug, Caplyta (lumateperone). The agreement comes as Sandoz submitted an abbreviated new drug application, signaling progress in the generic market.
Intra-Cellular stock gains on Sandoz deal (ITCI:NASDAQ)
Sandoz Group AG Intra-Cellular Therapies, Inc. USA
Regulatory & Legal, Market Report
17:05 10.01.2025

intra-cellular therapies and sandoz settle patent litigation over caplyta

Intra-Cellular Therapies has settled patent litigation with Sandoz regarding its product CAPLYTA® (lumateperone). The agreement allows Sandoz to market a generic version starting July 1, 2040, or earlier under specific conditions, following Sandoz's submission of an Abbreviated New Drug Application. Intra-Cellular will submit the settlement to the U.S. Federal Trade Commission and the U.S. Department of Justice, while other related litigation remains ongoing.
The Manila Times
Intra-Cellular Therapies, Inc. USA Juan Sanchez
Regulatory & Legal, Press Release
12:51 10.01.2025

congestive heart failure market poised for significant growth by 2034

The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
Barchart.com
United States Dollar Mesoblast Ltd Eli Lilly and Co Boehringer Ingelheim KG Bayer AG Merck & Co., Inc. Bristol-Myers Squibb Co Intra-Cellular Therapies, Inc. BioCardia, Inc. Novo Nordisk A/S scPharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. Cytokinetics, Incorporated Novartis AG Tenax Therapeutics, Inc. AstraZeneca PLC Amgen Inc. Otsuka Pharmaceutical Co. Ltd. FRA DEU ITA JPN GBR USA Show more
Healthcare, Market Report
15:50 07.01.2025
Trending
Subcategory
Industry Trends Stock Market Updates Corporate News Retail and Consumer Goods Finance Mergers & Acquisitions Global Financial Events Startups & Entrepreneurship AI Innovations Government Policies Market Analysis and Predictions Supply Chain Management Central Bank Actions Industry Mergers & Acquisitions Funding Rounds & Investments Domestic Politics Banking Regulations Global Trade Developments Cryptocurrency Trends Emerging Startups Hedge Funds & Private Equity
Countries:
USA CHN GBR ARE JPN IND SAU KWT DEU AUS SGP CAN HKG BRA CHE QAT ITA JOR FIN POL
Companies:
NVIDIA Corporation Apple Inc. Tesla, Inc. Huawei Technologies CO. Ltd. American Express Co The Goldman Sachs Group, Inc. Bank of America Corporation Citigroup Inc. Tiktok USD Barclays PLC Wells Fargo & Company HSBC Holdings plc International Monetary Fund FUND Coca-Cola FEMSA, S.A.B. de C.V. Nintendo Co., Ltd. Raiffeisen Bank International AG Berkshire Hathaway Inc. Pfizer Inc. VP Bank AG Williams-Sonoma, Inc.
Currencies:
United States Dollar Euro Japanese Yen United Arab Emirates Dirham Chinese Yuan Swiss Franc British Pound Sterling Offshore Chinese Yuan Indian Rupee Brazilian Real Saudi Riyal Australian Dollar South Korean Won Hong Kong Dollar
People:
Donald Trump Elon Musk Warren Buffett Joe Biden Jean Du Boullay Scott Bessent Riad Djabri Barack Obama George W. Bush Adey Salamin Nasir Alsharif Saygin Yalcin Khaldoon Tabaza Urs Monstein Jeffrey Howie Tony Xu David O. Sacks Feng Xiaotong Liu De Arthur Gensler

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.